If you don’t understand the follow-up professional description, just read this text in two minutes.
Condition overview
In April 2016, Mr. Xi developed painless hematuria with the naked eye, and was diagnosed with bladder cancer after further examination. He underwent bladder cancer resection immediately. The postoperative pathology showed high-grade urothelial carcinoma, invading the lamina propria (no muscle layer). The postoperative staging was T1N0M0. Birubicin intravesical instillation was started in April 2016 until December 2016.
However, the operation was not completely cured. In December 2016 and September 2017, cystoscopic resection was performed for multiple recurrences. On September 21, 2017, the pathology showed: (bladder mass) high-grade invasive urothelial carcinoma, vascular tumor thrombus was seen, and the tumor invaded the lamina propria without involving smooth muscle.
At the beginning of 2018, the iliac vessel metastasis was found in the re-examination, and four cycles of chemotherapy were given. The plan was: gemcitabine + cisplatin.
The re-examination in 2019 found more progress. The retroperitoneal, iliac vascular lymph nodes, and parapsoas nodules increased and enlarged compared with before. Considering the metastasis, Mr. Xi had to perform 6-cycle chemotherapy of albumin paclitaxel + carboplatin again.
division
general
Small
Know
knowledge
Bladder Cancer
Bladder cancer is a malignant tumor that occurs on the bladder mucosa and is the most common malignant tumor of the urinary system. Bladder cancer is divided into non-muscle-invasive urothelial carcinoma and muscle-invasive urothelial carcinoma. Patients with non-muscle-invasive urothelial carcinoma are mostly treated with transurethral resection of bladder tumor, and postoperative intravesical infusion therapy is used to prevent bladder cancer. Recurrence, such as Mr. Xi’s pathology, did not find invasion of the muscle layer, so electrosurgery was used for treatment. Muscle-invasive urothelial carcinoma is often treated with total cystectomy. The most important thing for tumors is prevention. Only by paying attention to our own behavior and protecting the bladder can we reduce the probability of bladder cancer.
Common causes of bladder cancer:
1. Smoking: Compared with non-smokers, smokers are more than twice as likely to have bladder cancer.
2. Bladder stones: Bladder stones can cause long-term chronic irritation to the bladder, which may lead to cancerous changes during repeated stimulation.
3. Occupational environment: intermediate products in the manufacture of dyes or antioxidants in the rubber and plastics industry. These chemical production processes contain B-naphthylamine, benzidine, 4-aminobisbiphenyl, etc., and long-term exposure to these substances is prone to bladder cancer.
Through a friend’s recommendation, Mr. Xi contacted the team of Professor Zhang Minghui of Tsinghua University School of Medicine. After reading Mr. Xi’s medical records, Professor Zhang Minghui made the following analysis and judgment:
1. The patient was diagnosed with bladder tumor in time and underwent radical resection, and completed postoperative conventional chemotherapy. Fortunately, the clinical stage was earlier.
2. However, there are high-risk factors in the pathological results – “high-grade tumor” and “vascular tumor thrombus”, and the traditional surgery + chemotherapy regimen cannot solve the problem of recurrence and metastasis very well. Mr. Xi relapsed in only 6 months, and within 2 years, after 3 operations and 2 chemotherapy, he was still uncontrolled, and the iliac blood vessel metastasis appeared again after that. Multiple treatments have also brought him a lot of side effects.
3. In order to prevent the 5th recurrence or metastasis, it is necessary to take treatment that has not been tried before. NKT cell immunotherapy has unique advantages for patients like Mr. Xi. It can kill residual tumor cells, prevent the accumulation of free cancer cells, and can effectively reduce the risk of metastasis and recurrence. It has no obvious side effects and is patient-friendly.
Mr. Xi took NKT cell immunotherapy in 2020.5, and has completed 22 courses of treatment for a total of 27 months (as of 2022.8). During this period, no obvious signs of tumor progression were found in repeated examinations, and the overall evaluation is stable!
Image aspect
,
swollen mark
Tumor marker status: 2020.4 Check PSA: 0.46ng/ml is in the normal range (normal ≤4.0ng/ml). There was no monitoring after the swollen mark. Pay attention to follow-up and closely observe the changes.
Quality of Life
In more than two years of NKT treatment, Mr. Xi’s physical condition has been significantly improved, his body weight has increased by 1-3KG, and he has reported less cold and fever in spring and winter than before.
in conclusion
Mr. Xi achieved his desired therapeutic goal after adopting NKT cell therapy. Now nearly two years have passed, and the latest assessment results are still stable with no progress . After multiple chemotherapy regimens of different regimens did not solve the problem of recurrence, after using NKT treatment, Mr. Xi’s condition has achieved good stability.
Popular science knowledge is for reference only, and individual patients are subject to clinical medical treatment.
NKT Classic Case Review